Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4556 Gene Editing

Closed Independence Day 07-02 16:00:00 EDT

550.07

+29.59

+5.68%

High564.67	Low522.33	Vol13.61M
Open522.33	D1 Closing520.49	Amplitude8.13%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O343.26M	T/O Rate--	Tradable Shares0.00
P/B3.201066	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":550.0721,"timestamp":1783022399999,"preClose":520.487,"halted":0,"volume":13609874,"delay":0,"changeRate":0.056841,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed Independence Day","change":29.585083,"latestTime":"07-02 16:00:00 EDT","open":522.32886,"high":564.665,"low":522.32886,"amount":343262895.976994,"amplitude":0.081339,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.201066,"peRate":-10.138035,"turnoverRate":0.029089,"increases":4,"decrements":0,"flats":0,"marketCap":12386016832,"floatMarketCap":11588254784},"requestUrl":"/m/hq/s/BK4556/tweets","defaultTab":"tweets","newsList":[{"id":"2648252565","title":"Beam Therapeutics CEO John M. Evans Disposes of 49,000 Common Shares Worth $1.72 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2648252565","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648252565?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:05","pubTimestamp":1782936351,"startTime":"0","endTime":"0","summary":"Beam Therapeutics CEO John M. Evans disposes of 49,000 common shares worth $1.72 millionBeam Therapeutics CEO John M. Evans exercised stock options for 50,000 common shares on June 29-30, 2026 at USD ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL8mq8Xp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Beam Therapeutics CEO John M. Evans Disposes of 49,000 Common Shares Worth $1.72 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4139","LU1861558580.USD","BK4585","LU1861559042.SGD","BEAM","BK4505","BK4588","BK4556","BK4611"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167664576","title":"CRISPR Gene Editing Therapy Shows Groundbreaking Efficacy in Pediatric Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1167664576","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167664576?lang=en_us&edition=fundamental","pubTime":"2026-06-30 04:00","pubTimestamp":1782763234,"startTime":"0","endTime":"0","summary":" HCA Healthcare Inc (HCA) announced on Monday that a gene editing therapy study it participated in has been published in the New England Journal of Medicine, showing positive results for children...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B775SV38.USD","LU0310799852.SGD","BK4139","LU0648001328.SGD","LU0433182093.SGD","LU0985489474.SGD","IE00B3S45H60.SGD","LU1261432733.SGD","LU1201861249.SGD","SG9999014013.SGD","LU0882574055.USD","SG9999014005.SGD","BK4185","LU1861559042.SGD","LU2355687059.USD","LU1267930490.SGD","LU0980610538.SGD","LU0878866978.SGD","LU2244417387.USD","BK4588","BK4585","LU0114720955.EUR","BK4504","LU0868494617.USD","SG9999014021.USD","LU1489326972.SGD","BK4611","CRSP","LU0068578508.USD","LU0310800379.SGD","LU0708994859.HKD","LU0128525929.USD","LU0187121727.USD","LU1119994496.HKD","LU0130102774.USD","LU1861558580.USD","LU0029864427.USD","LU1150488135.SGD","LU1150488218.USD","SG9999014039.USD","LU0203345920.USD","BK4556","LU0203347892.USD","LU1084165304.USD","LU0211327993.USD","LU0211328371.USD","HCA","LU1267930573.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647094643","title":"FMR Reports $10.04 Million Beam Therapeutics Common Share Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2647094643","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647094643?lang=en_us&edition=fundamental","pubTime":"2026-06-30 02:18","pubTimestamp":1782757081,"startTime":"0","endTime":"0","summary":"FMR reports $10.04 million Beam Therapeutics common share saleFMR sold 284,860 Beam Therapeutics common shares on June 25-26 at weighted average prices of $35.12 and $35.26.Stake held via F-Prime Capi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL6tBkfj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"FMR Reports $10.04 Million Beam Therapeutics Common Share Sale","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1861559042.SGD","BK4505","BK4611","BK4585","LU1861558580.USD","BEAM","BK4556","BK4535","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647022371","title":"HCA Healthcare announces research published in NEJM on CRISPR-based therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2647022371","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647022371?lang=en_us&edition=fundamental","pubTime":"2026-06-29 20:35","pubTimestamp":1782736519,"startTime":"0","endTime":"0","summary":"HCA Healthcare (HCA) announced new research published in The New England Journal of Medicine, NEJM, demonstrating promising results from a gene-edi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hca-healthcare-announces-research-published-in-nejm-on-crispr-based-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hca-healthcare-announces-research-published-in-nejm-on-crispr-based-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B775SV38.USD","LU0310799852.SGD","BK4139","LU0433182093.SGD","XLV","LU0985489474.SGD","IE00B3S45H60.SGD","LU1261432733.SGD","LU1201861249.SGD","SG9999014013.SGD","SG9999014005.SGD","BK4185","LU1861559042.SGD","LU2355687059.USD","LU1267930490.SGD","LU0980610538.SGD","LU0878866978.SGD","LU2244417387.USD","BK4588","BK4585","LU0114720955.EUR","BK4504","LU0868494617.USD","SG9999014021.USD","LU1489326972.SGD","BK4611","CRSP","LU0068578508.USD","LU0310800379.SGD","LU0708994859.HKD","LU0128525929.USD","XBI","LU0187121727.USD","LU1119994496.HKD","LU0130102774.USD","LABU","LU1861558580.USD","LU0029864427.USD","LU1150488135.SGD","LU1150488218.USD","SG9999014039.USD","BK4581","LU0203345920.USD","BK4556","LU0203347892.USD","LU1084165304.USD","LU0211327993.USD","LU0211328371.USD","HCA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646365843","title":"Beam Therapeutics (BEAM) Could Be 78% Undervalued As FDA Clears BEAM 304","url":"https://stock-news.laohu8.com/highlight/detail?id=2646365843","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646365843?lang=en_us&edition=fundamental","pubTime":"2026-06-25 01:32","pubTimestamp":1782322362,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) stock is in focus after the FDA cleared its investigational new drug application for BEAM-304, an in vivo base editing therapy targeting phenylketonuria, a rare inherited metabolic disorder.\nSee our latest analysis for Beam Therapeutics.\nBeam Therapeutics shares trade at US$33.20 after a 1 day share price decline of 6.56%, while the 30 day share price return of 15.92% and 1 year total shareholder return of 93.59% point to momentum that has recently strengthened around...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/beam-therapeutics-beam-could-be-78-undervalued-as-fda-clears","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/beam-therapeutics-beam-could-be-78-undervalued-as-fda-clears","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1861558580.USD","BK4556","BK4585","LABU","BK4611","BEAM","BK4588","BK4139","LU1861559042.SGD","BK4505","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645851907","title":"Sangamo amends 8-K to file asset purchase agreement exhibits","url":"https://stock-news.laohu8.com/highlight/detail?id=2645851907","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645851907?lang=en_us&edition=fundamental","pubTime":"2026-06-24 04:42","pubTimestamp":1782247372,"startTime":"0","endTime":"0","summary":"Sangamo Therapeutics filed an amended Form 8-K to add two previously omitted exhibits to its June 23, 2026 report.The amendment filed the June 22, 2026 asset purchase agreements involving Eli Lilly and Astellas Gene Therapies.No other disclosures in the original 8-K were changed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL7BrXgD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SGMO","BK4556","SGMOQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645853089","title":"Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle","url":"https://stock-news.laohu8.com/highlight/detail?id=2645853089","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645853089?lang=en_us&edition=fundamental","pubTime":"2026-06-24 01:46","pubTimestamp":1782236760,"startTime":"0","endTime":"0","summary":"Sangamo files for Chapter 11 as Eli Lilly and Astellas step in to buy its valuable gene therapy and genome-editing assets.","market":"sh","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/06/23/Gene-editing.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=240,format=auto,quality=85/files/images/story/2026/06/23/Gene-editing.jpg"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/m-a/26/06/60053151/sangamo-bankruptcy-puts-gene-therapy-platforms-in-play-eli-lilly-and-astellas-circle","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/m-a/26/06/60053151/sangamo-bankruptcy-puts-gene-therapy-platforms-in-play-eli-lilly-and-astellas-circle","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SGMOQ","SGMO","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645839359","title":"Sangamo Therapeutics - Eli Lilly to Buy Sangamo Assets for $50 Mln Plus Assumption of Liabilities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2645839359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645839359?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:47","pubTimestamp":1782218830,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nFWN42V0DG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GB00BDT5M118.USD","IE00BN29S564.USD","LU0820562030.AUD","IE0004445015.USD","LU1720051108.HKD","ELIL","LU0079474960.USD","LU2471134952.CNY","IE00BFSS7M15.SGD","LU0353189763.USD","LU2089284900.SGD","LU0823434740.USD","SG9999018857.SGD","LU0133085943.USD","IE00BJT1NW94.SGD","IE00BJJMRX11.SGD","LU1629891620.HKD","LU2023251221.USD","LU0210536198.USD","LU1366192091.USD","LU2491050071.SGD","IE00BJJMRZ35.SGD","LU2089283258.USD","BK4516","LU0238689110.USD","LU0708995401.HKD","LU0820561909.HKD","LU0943347566.SGD","LU1804176565.USD","LU1868837136.USD","LU2271345857.HKD","IE00B1XK9C88.USD","SGXZ51526630.SGD","LU0432979614.USD","LU0256863902.USD","LU2108987350.USD","LU2417539215.USD","IE00BKDWB100.SGD","LU2491049909.HKD","LU2361044865.SGD","BK4585","LU0640476718.USD","LU1712237335.SGD","IE00BFSS8Q28.SGD","LU0882574139.USD","LU0096364046.USD","IE00B7KXQ091.USD","LU2471134523.USD","SG9999015952.SGD","LU1974910355.USD","IE00BWXC8680.SGD","LU0109391861.USD","LU2236285917.USD","SGMO","LU2211815571.USD","SG9999001176.SGD","LU0882574055.USD","LU0471298694.HKD","LU2746668461.USD","BK4007","LU1551013342.USD","LU2089984988.USD","LU2357305700.SGD","LU1868836914.USD","LU1868836757.USD","IE00BJLML261.HKD","IE0002141913.USD","LU2168564495.EUR","LU1145028129.USD","SG9999001176.USD","IE00BK4W5M84.HKD","LU2168564222.USD","LU0417517546.SGD","LU2237443549.SGD","LU0320765992.SGD","LU0266013472.USD","LU2168564149.EUR","LU0471298777.SGD","LU1623119135.USD","BK4139","LU0385154629.USD","LU1988902786.USD","LLII","IE00B2B36J28.USD","BK4599","LU2237443622.USD","BK4534","LU0061475181.USD","LU0203201768.USD","LU1989771016.USD","SGXZ57979304.SGD","LU2602419157.SGD","LU1814569148.SGD","SGXZ99366536.SGD","LU0683600562.USD","SG9999014914.USD","IE0004445239.USD","LU0354030438.USD","LU2361044949.HKD","BK4533","LU0823416689.USD","LU1064131342.USD","LU0006306889.USD","LU0158827948.USD","LU0158827781.USD","IE00B775H168.HKD","LU0256863811.USD","LU1868836591.USD","LU2168564065.EUR","BK4588","IE00BFTCPJ56.SGD","LU1069344957.HKD","LU1267930730.SGD","LU2023250330.USD","LU1057294990.SGD","SGXZ31699556.SGD","LU1127390331.HKD","LU2756315318.SGD","BK4581","LU0320765059.SGD","IE00BJJMRY28.SGD","LU1868837300.USD","LU2456880835.USD","SG9999015945.SGD","LU0094547139.USD","LU1983299246.USD","LU0466842654.USD","LU1093756168.USD","LU1323610961.USD","LU0097036916.USD","LLY","LU0058720904.USD","LU2746668974.SGD","LU2111349929.HKD","LU2265009873.SGD","LU2324357040.USD","LU2462157665.USD","LU2087625088.SGD","LU1280957306.USD","SGXZ81514606.USD","LU0114720955.EUR","LU2756315664.SGD","LU2063271972.USD","LU2461242641.AUD","LU2106854487.HKD","LU0354030511.USD","LU2237443465.HKD","IE00BK4W5L77.USD","LU0234572021.USD","LU0820561818.USD","SG9999014880.SGD","IE00BKPKM429.USD","IE00B4R5TH58.HKD","LU2112291526.USD","SG9999015986.USD","LU2360106947.USD","LU0203202063.USD","LLYX","LU2264538146.SGD","LU2471134879.HKD","SG9999018865.SGD","LU2237438978.USD","LU1291159041.SGD","LLYZ","LU0353189680.USD","LU2552382058.USD","LU0689472784.USD","LU1061106388.HKD","LU0964807845.USD","SG9999014898.SGD","LU1035775433.USD","LU2237443382.USD","SG9999015978.USD","LU1551013425.SGD","ELIS","BK4556","IE0009355771.USD","LU2213496289.HKD","LU0198837287.USD","IE0001KFT4U8.USD","SG9999014906.USD","LU0889565916.HKD","SG9999017495.SGD","IE0005OL40V9.USD","LU0823434583.USD","LU2552382215.SGD","LU0106261372.USD","LU0787776722.HKD","LU2237443895.HKD","LU0225283273.USD","LU0316494557.USD","LU1548497426.USD","LU2471134796.USD","LU2750360641.GBP","LU2491050154.USD","LU1023059063.AUD","SG9999013999.USD","SGMOQ","LU0109394709.USD","LU2023250504.SGD","LU0323591593.USD","LU1232071149.USD","LU2028103732.USD","LU0289739699.SGD","LU1093756325.SGD","LU2468319806.SGD","LU2896262040.SGD","LU0786609619.USD","LU2750360997.AUD","LU2552382132.HKD","LU2237443978.SGD","LU0122379950.USD","IE00B1BXHZ80.USD","LU2361045086.USD","LU1917777945.USD","LU1720051017.SGD","IE00B4JS1V06.HKD","LU0456855351.SGD","LU2168563687.JPY","LU0672654240.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645393928","title":"Sangamo Therapeutics: Expects Restructuring to Result in Elimination of About 51 Roles in United States, or About 40% of Company's Workforce","url":"https://stock-news.laohu8.com/highlight/detail?id=2645393928","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645393928?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:47","pubTimestamp":1782218830,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nFWN42V0DG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMO","SGMOQ","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645369839","title":"Sangamo Therapeutics: Astellas to Buy Co's Assets for $25 Mln Payable at Closing Plus up to Extra $25 Mln Payable on Achievement of Some Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2645369839","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645369839?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:47","pubTimestamp":1782218830,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nFWN42V0DG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","BK4139","SGMOQ","ALPMF","SGMO","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645393678","title":"Sangamo lines up up to $30 million debtor-in-possession loan from Northridge ATM amid Chapter 11 filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2645393678","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645393678?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:47","pubTimestamp":1782218827,"startTime":"0","endTime":"0","summary":"Sangamo entered a debtor-in-possession financing agreement with Northridge ATM for up to USD 30 million as it filed for Chapter 11.Facility would be senior secured, backed by a first-priority lien on substantially all assets, with a superpriority claim.Company is seeking court authority for an initial draw up to USD 10.5 million, followed by final approval for the full facility.Maturity set for the earliest of Dec. 30, 2026, plan effectiveness, certain default-related acceleration, or other specified Chapter 11 milestones.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL7Zbnqc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGMO","BK4139","SGMOQ","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645783572","title":"Sangamo Therapeutics files for Chapter 11 as Lilly, Astellas anchor asset sale bids","url":"https://stock-news.laohu8.com/highlight/detail?id=2645783572","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645783572?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:05","pubTimestamp":1782216321,"startTime":"0","endTime":"0","summary":"Sangamo Therapeutics filed for voluntary Chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware.Process targets a court-supervised auction of substantially all assets, with sales expected to run under Section 363.Lilly signed a stalking-horse deal for key technology platforms and the ST-506 prion disease program.Astellas signed a stalking-horse deal for the ST-920 Fabry disease gene therapy program.DIP financing commitment secured from Northridge ATM to support operations during the Chapter 11 process, subject to court approval.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDLcd2D0v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","BK4585","SGMO","IE00BKPKM429.USD","SGMOQ","NDAQ","BK4556","BK4588","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","BK4112","SG9999014021.USD","LU2095319765.USD","IE00BN0W2W23.USD","SG9999014039.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645835757","title":"Sangamo Therapeutics - St-503, Giroctocogene Fitelparvovec, and Cell Therapy Assets Remain Available for Bidders","url":"https://stock-news.laohu8.com/highlight/detail?id=2645835757","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645835757?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:05","pubTimestamp":1782216300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUAQFBXF:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMOQ","SGMO","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645835755","title":"Sangamo Therapeutics - Commences Voluntary Chapter 11 Proceedings for Reorganization and Asset Auction","url":"https://stock-news.laohu8.com/highlight/detail?id=2645835755","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645835755?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:05","pubTimestamp":1782216300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUAQFBXF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMOQ","SGMO","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645835200","title":"Sangamo Therapeutics Enters Into Asset Sale Agreements With Lilly and Astellas","url":"https://stock-news.laohu8.com/highlight/detail?id=2645835200","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645835200?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:05","pubTimestamp":1782216300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUAQFBXF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMO","SGMOQ","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645758835","title":"Sangamo Therapeutics - Lilly and Astellas to Serve as Stalking Horse Bidders for Asset Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2645758835","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645758835?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:05","pubTimestamp":1782216300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUAQFBXF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMO","BK4556","BK4139","SGMOQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645383575","title":"Sangamo Therapeutics - Secures Dip Financing Commitment From Northridge Atm","url":"https://stock-news.laohu8.com/highlight/detail?id=2645383575","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645383575?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:05","pubTimestamp":1782216300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUAQFBXF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4556","SGMO","SGMOQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645711010","title":"Thanks to SpaceX, Index Funds Won't Track Each Other as Closely. Here's One Pro's Advice. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2645711010","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645711010?lang=en_us&edition=fundamental","pubTime":"2026-06-23 01:47","pubTimestamp":1782150420,"startTime":"0","endTime":"0","summary":"In the pre-SpaceX days, it didn't really matter which major index benchmark an investor chose, whether it was constructed by Standard & Poor's, the Center for Research in Security Prices , or FTSE Russell. They all returned essentially the same amount.Over the past 25 years the range of annualized returns for the S&P 500 index, the Russell 1000 index, and the CRSP US Large Cap indexes was 9.63% to 9.72%. In other words, after 2 1/2 decades, just 0.09 percentage point, or nine basis points, separated the best performer from the worst. In dollar terms, a $1,000 investment in each of the three indexes  would have yielded terminal values that ranged from $9,880 to $10,090, a $200 difference.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VEU","BK4611","VTI","SPYU","UPRO","MOAT","GSLC","ALLW","SPYD","XLG","BK4559","SPMO","SPUU","VBK","SMAX","BK4534","BK4581","ETFT","SPY","RSPA","SPDN","SPYH","SPUS","BK4139","NOBL","IVW","YSPY",".SPX","LU1861558580.USD","SFY","JEPI","SPYM","BK4564","SPXL","IVE","HIBS","RSPU","BMAY","IJH","SDS","BK4562","SPXU","HIBL","GPIX","SPHQ","SPCE","VV","BK4615","BK4585","TSPY","IJR","LU1861559042.SGD","DBSC","BK4588","VOO","CRSP","BK4187","VTV","SPGP","SCHX","SPHD","DMAX","SPYG","SPXS","RSP","XYLD","MMAX","SCHB","SPLV","SH","ACWI","SPYQ","BK4556","RSPN","SSO","ITOT","IVV","XDTE","VOOG","SPYV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644065494","title":"Why Beam Therapeutics (BEAM) Is Up 16.1% After FDA Clears Platform-Based PKU Gene-Editing Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2644065494","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644065494?lang=en_us&edition=fundamental","pubTime":"2026-06-20 02:42","pubTimestamp":1781894523,"startTime":"0","endTime":"0","summary":"Beam Therapeutics recently received FDA clearance for its IND application for BEAM-304, an in vivo base-editing therapy delivered via LNP infusion to correct PAH gene mutations in patients with phenylketonuria.\nThe program’s platform design, allowing multiple mutation-specific base editors to be advanced under a single clinical trial in alignment with emerging FDA guidance, could be an important proof point for Beam’s broader base-editing approach in liver diseases.\nWe’ll now explore how FDA...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/why-beam-therapeutics-beam-is-up-161-after-fda-clears-platfo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/why-beam-therapeutics-beam-is-up-161-after-fda-clears-platfo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4585","BK4535","BK4505","BK4611","BK4588","BEAM","LU1861559042.SGD","BK4556","BK4139","LABU","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644031775","title":"Editas Medicine Shareholders Back Board, Pay and Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2644031775","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644031775?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:50","pubTimestamp":1781819405,"startTime":"0","endTime":"0","summary":"An announcement from Editas Medicine ( ($EDIT) ) is now available. At its June 17, 2026 annual meeting, Editas Medicine stockholders elected Bernad...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/editas-medicine-shareholders-back-board-pay-and-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/editas-medicine-shareholders-back-board-pay-and-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4556","nameEN":"BK4556"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Gene Editing(BK4556) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Gene Editing,BK4556,Gene Editing股票,Gene Editing股票老虎,Gene Editing股票老虎国际,Gene Editing行情,Gene Editing股票行情,Gene Editing股价,Gene Editing股市,Gene Editing股票价格,Gene Editing股票交易,Gene Editing股票购买,Gene Editing股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Gene Editing(BK4556) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction